ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

RVA Reva Medical Inc

0.17
0.00 (0.00%)
14 May 2024 - Closed
Delayed by 20 minutes
Share Name Share Symbol Market Type
Reva Medical Inc ASX:RVA Australian Stock Exchange Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.17 0.175 0.19 0.00 01:00:00

REVA Presentation at Wells Fargo 2012 Healthcare Conference

13/06/2012 1:25am

GlobeNewswire Inc.


Reva Medical (ASX:RVA)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Reva Medical Charts.

REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce that its Chairman and Chief Executive Officer, Robert Stockman, is scheduled to present at the Wells Fargo Securities 2012 Healthcare Conference at 8:00 a.m. US EDT on Tuesday, June 19, 2012. The conference is being held June 19 and 20, 2012 at the Intercontinental Hotel in Boston, Massachusetts.

A copy of the presentation materials will be available on REVA's website at www.revamedical.com shortly before the presentation.

About REVA

REVA is a development stage medical device company incorporated in Delaware, USA that is focused on the development and eventual commercialization of its proprietary, bioresorbable stent products. REVA's principal product, the ReZolveĀ® scaffold, combines REVA's proprietary stent design with a proprietary polymer that is metabolized and cleared from the body. The ReZolve scaffold is designed to offer full x-ray visibility, clinically relevant sizing and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of scaffold structure over time, the ReZolve scaffold may reduce the incidence of late forming blood clots, or thrombosis, a rare but serious problem associated with drug-eluting metal stents currently on the market. REVA will require clinical results and regulatory approval before it can begin selling the ReZolve scaffold.

The REVA Medical, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8505

CONTACT: United States
         
         Investor and Media Enquiries:
         Cheryl Liberatore
         Director, Investor Relations and Marketing
         REVA Medical, Inc.
         +1 858 966-3045
         
         Australia
         
         Investor Enquiries:
         David Allen or Alan Taylor
         Inteq Limited
         +61 2 9231 3322
         
         Media Enquiries:
         Katie Mackenzie or Rebecca Wilson
         Buchan Consulting
         +61 3 9866 4722

1 Year Reva Medical Chart

1 Year Reva Medical Chart

1 Month Reva Medical Chart

1 Month Reva Medical Chart

Your Recent History

Delayed Upgrade Clock